Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021
Brooklyn ImmunoTherapeutics, focused on cytokine and gene editing therapies, will present at the SNN Virtual Investor Conference from August 17-19, 2021. CEO Howard J. Federoff will deliver a corporate overview on August 18 at 12:00 PM ET. Investors can schedule one-on-one meetings during the event. Brooklyn's lead program, IRX-2, is in Phase 2B trials for head and neck cancer, showing promise in previous trials. The company is advancing multiple therapies for various conditions, including cancer and rare genetic diseases. More information can be found on their official website.
- None.
- None.
NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the SNN Virtual Investor Conference being held August 17 – 19, 2021.
Dr. Federoff will deliver his corporate presentation on August 18 at 12:00pm ET.
Investors can also request a one-on-one meeting with Dr. Federoff to be arranged throughout the conference.
Investors can register here: REGISTER
About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases.
Brooklyn’s most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.
Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.
Investor Relations Contact:
CORE IR
516-222-2560
investors@brooklynitx.com
Media Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
FAQ
When will Brooklyn ImmunoTherapeutics present at the SNN Virtual Investor Conference?
What is Brooklyn ImmunoTherapeutics' lead program?
What stage is the IRX-2 program currently in?
Can investors meet with the CEO at the conference?
What areas is Brooklyn ImmunoTherapeutics exploring for treatment?
